Inland Peptides
Inland Peptides

LL-37

Research Snapshot Last reviewed October 2026
No

Approved by the FDA for human use

Yes

Studied in human clinical trials

Yes

Published human research

Yes

Published animal research

Primary research areas
  • Wound healing and antimicrobial activity

Overview

LL-37 is a peptide made of 37 amino acids and part of the body’s defenses against infection. Researchers study its antibacterial activity and role in wound healing.

LL-37 is not approved by the Food and Drug Administration for human use, and no prescription version exists. It should only be used within an approved clinical study and never taken without a doctor’s authorization.

What is it being studied for?

Research is focused on chronic wounds that will not close, particularly venous leg ulcers, and on bacterial infection.

LL-37 can damage bacterial membranes. It also affects signals involved in skin cell movement and blood vessel growth during wound repair.

What has research found?

A small placebo-controlled study found faster wound healing with lower concentrations of LL-37 applied to venous leg ulcers. A later trial involving 148 patients found no significant improvement in healing across the full study group.

Animal and laboratory studies have examined LL-37’s role in wound repair. It is also found in healing human skin wounds.

The human trials tested LL-37 applied to wounds, rather than injected.

FDA status and development history

LL-37 was identified in the 1990s. Human trials have examined topical wound treatments. It is not FDA-approved.